A5006758102- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- SARS-CoV-2 and COVID-19 Research
- Bone health and treatments
- COVID-19 Clinical Research Studies
- Quinazolinone synthesis and applications
- Spine and Intervertebral Disc Pathology
- Natural Compounds in Disease Treatment
- Management of metastatic bone disease
- Cancer Immunotherapy and Biomarkers
- Cancer Mechanisms and Therapy
- Computational Drug Discovery Methods
- Chemokine receptors and signaling
- Ubiquitin and proteasome pathways
- Thallium and Germanium Studies
- Spinal Fractures and Fixation Techniques
- COVID-19 Impact on Reproduction
Peking Union Medical College Hospital
2022-2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2022-2025
Immunotherapy is a significant risk factor for severe COVID-19 in multiple myeloma (MM) patients. Understanding how immunotherapies lead to crucial improving patient outcomes. Human protein microarrays were used examine the expression of 440 molecules MM patients treated with bispecific T-cell engagers (BiTe) (n = 9), anti-CD38 monoclonal antibodies (mAbs) 10), and proteasome inhibitor (PI)-based regimens 10). Differentially expressed proteins (DEPs) identified analyzed using bioinformatics....
Abstract An 83-year-old woman with newly diagnosed multiple myeloma (MM) was enrolled in our 68 Ga-pentixather and Ga-pentixafor PET/CT trial for evaluation of tumor burden. detected more focal bone lesions, the uptake levels lesions on were higher than those PET/CT. This suggests that may be an alternative imaging modality sensitive detecting MM
Abstract Background Myc rearrangement (Myc‐R) is a controversial factor linked to adverse outcomes in newly diagnosed multiple myeloma (NDMM). Aims This study aimed evaluate the impact of Myc‐R on prognosis NDMM patients and its role risk stratification compared with traditional high‐risk cytogenetic abnormalities (HRCAs). Materials & Methods A total 417 enrolled from May 2009 September 2022 were included. Fluorescence situ hybridization (FISH) was used detect other (Myc‐OA). Median...
Abstract Background This study assessed the effect of standardized efficacy markers on prognosis in patients with newly diagnosed multiple myeloma (MM) during induction phase treatment bortezomib, cyclophosphamide, and dexamethasone (BCD). Methods We retrospectively analyzed clinical data 197 MM treated BCD as front‐line regimen at Peking Union Medical College Hospital from January 1, 2013 to December 31, 2018. Results There were 107 International Staging System (ISS) III 51 paraprotein...
To evaluate the efficacy and prognosis of percutaneous vertebroplasty/kyphoplasty (PVP/PKP) in patients with newly diagnosed multiple myeloma (NDMM).
At the end of 2022, a huge tide SARS-CoV-2 infection mainly Omicron BA.4/5 developed in China. Multiple myeloma (MM) patients suffered cancer deterioration and mortality from COVID-19, yet profound analyses variants-induced immunity function are scarce. We presented longitudinal study 218 MM 73 healthy controls (HCs), reporting prognostic factors dynamic humoral cellular immune responses. Neutralizing antibody interferon γ ELISpot assay was tested at three time points: 2-4, 8-10, 14-16 weeks...
Background Broad T cell phenotypic alterations and potential dysfunctions were prominent in COVID-19. There are few inconclusive data about the role of immune checkpoints for exhaustion/activation during SARS-CoV-2 infection multiple myeloma (MM) patients. Methods We tested subsets 177 MM patients with COVID-19, as well 32 healthy infected controls 42 uninfected The percentage CD4+ CD8+ subpopulation (PD-1, TIGIT, TIM-3, LAG-3, CTLA-4, OX40, 4-1BB) evaluated by flow cytometry. Results have...